ArticleDiscover oncology2026
Higher frequency of circulating regulatory T cells is associated with poor outcomes in patients with colorectal cancer.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundWhile immune dysregulation significantly influences colorectal cancer (CRC) progression, this study aimed to investigate the levels of circulating regulatory T cells (cTreg) and their subsets, follicular helper T cells (cTfh), and follicular regulatory T cells (cTfr) in patients with CRC and to evaluate their prognostic significance.
methodsWe enrolled 120 patients with CRC (January 2021 to September 2022) and 91 healthy controls (HCs). Flow cytometry was used to quantify the frequency of cTregs and their subsets (resting Tregs/activated Tregs), cTfh, and cTfr. Patients were prospectively followed up until April 2025, with overall survival (OS) as the primary endpoint. Univariable and multivariable Cox proportional hazards models were employed to identify significant prognostic factors for OS. Survival curves were generated using the Kaplan-Meier method and compared with the log-rank test.
resultsAfter a 35-month median follow-up, 22 patients with CRC had died (18.3% mortality rate). Patients with CRC had higher cTreg (7.43% vs. 6.33%, P < 0.001), cTfh (15.8% vs. 13.8%, P < 0.001), and cTfr (2.39% vs. 2.20%, P = 0.019) than HCs. Patients with advanced-stage CRC had higher cTreg levels than those with early-stage CRC (7.68% vs. 7.10%, P = 0.006). Higher frequency of cTreg levels (≥ 8.295%, area under the curve = 0.717) was correlated with shorter OS.
conclusionscTreg, cTfh, and cTfr levels are elevated in patients with CRC. An elevated cTreg frequency is associated with poor CRC prognosis. Assessment of cTreg levels may aid in prognostic assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.